The 56 references in paper O. Stetsyuk U., I. Andreeva V., R. Kozlov S., О. Стецюк У., И. Андреева В., Р. Козлов С. (2014) “Место внутривенной формы азитромицина в лечении внебольничной пневмонии // A role of intravenous formulation of azythromycin in treatment of community-acquired pneumonia” / spz:neicon:pulmonology:y:2012:i:1:p:103-111

1
Чучалин А.Г., Синопальников А.А., Козлов Р.С. и др. Внебольничная пневмония у взрослых: Практ. рекомендации по диагностике, лечению и профилактике: Пособие для врачей. Смоленск: МАКМАХ; 2010.
(check this in PDF content)
2
Woodhead M., Blasi F., Ewig S. et al. Guidelines for the management of adult lower respiratory tract infections – full version. Clin. Microbiol. Infect. 2011; 17 (Suppl. 6): E1– E59.
(check this in PDF content)
3
Mandell L.A., Wunderink R.G., Anzueto A. et al. Infectious Diseases Society of America / American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults. Clin. Infect. Dis. 2007; 44 (Suppl. 2): S27–S72.
(check this in PDF content)
4
Lim W.S., Baudouin S.V., George R.C. et al. BTS guidelines for the management of community acquired pneumonia in adults: update 2009. Thorax 2009; 64 (Suppl. 3): iii1–iii55.
(check this in PDF content)
5
Höffken G., Lorenz J., Kern W. et al.Guidelines of the PaulEhrlich-Society of Chemotherapy, the German Respiratory Diseases Society, the German Infectious Diseases Society and of the Competence Network CAPNETZ for the management of lower respiratory tract infections and community-acquired pneumonia. Pneumologie 2010; 64 (3): 149–154.
(check this in PDF content)
6
Menéndez R., Torres A., Aspa J. et al. Community acquired pneumonia. New guidelines of the Spanish Society of Chest Diseases and Thoracic Surgery (SEPAR). Arch. Bronconeumol. 2010; 46 (10): 543–558.
(check this in PDF content)
7
Corrêa R.A., Lundgren F.L., Pereira-Silva J.L. et al.Brazilian guidelines for community-acquired pneumonia in immunocompetent adults – 2009. J. Bras. Pneumol. 2009; 35 (6): 574–601.
(check this in PDF content)
8
Ferrer M., Menendez R., Amaro R., Torres A. The impact of guidelines on the outcomes of community-acquired and ventilator-associated pneumonia. Clin. Chest Med. 2011; 32 (3): 491–505.
(check this in PDF content)
9
Torres A., Ferrer M., Badia J.R. Treatment guidelines and outcomes of hospital-acquired and ventilator-associated pneumonia. Clin. Infect. Dis. 2010; 51 (Suppl. 1): S48–S53.
(check this in PDF content)
10
Sharpe B.A. Guideline-recommended antibiotics in community-acquired pneumonia: not perfect, but good. Arch. Intern. Med. 2009; 169 (16): 1462–1464.
(check this in PDF content)
11
Maxwell D.J., McIntosh K.A., Pulver L.K. et al.Empiric management of community-acquired pneumonia in Australian emergency departments. Med. J. Aust. 2005; 183 (10): 520–524.
(check this in PDF content)
12
Рачина С.А., Козлов Р.С., Шаль Е.П. и др.Анализ антибактериальной терапии госпитализированных пациентов с внебольничной пневмонией в различных регионах РФ: уроки многоцентрового фармакоэпидемиологического исследования. Клин. микробиол. и антимикроб. химиотер. 2009; 11 (1): 66–78.
(check this in PDF content)
13
Paul M., Nielsen A.D., Gafter-Gvili A. et al.The need formacrolides in hospitalised community-acquired pneumonia: propensity analysis. Eur. Respir. J. 2007; 30 (3): 525–531.
(check this in PDF content)
14
Lodise T.P., Kwa A., Cosler L. et al.Comparison of beta-lactam and macrolide combination therapy versus fluoroquinolone monotherapy in hospitalized Veterans Affairs patients with community-acquired pneumonia. Antimicrob.Agents Chemother. 2007; 51: 3977–3982.
(check this in PDF content)
15
Rodriguez A., Mendia A., Sirvent J.M. et al. Combination antibiotic therapy improves survival in patients with communityacquired pneumonia and shock. Crit. Care Med. 2007; 35 (6): 1493–1498.
(check this in PDF content)
16
Baddour L.M., Yu V.L., Klugman K.P. et al.Combination antibiotic therapy lowers mortality among severely ill patients with pneumococcal bacteremia. Am. J. Respir. Crit. Care Med. 2004; 170 (4): 440–444.
(check this in PDF content)
17
Amsden G.W. Anti-inflammatory effects of macrolides – an underappreciated benefit in the treatment of communityacquired respiratory tract infections and chronic inflammatory pulmonary conditions? J. Antimicrob. Chemother. 2005; 55 (1): 10–21.
(check this in PDF content)
18
Omura S., ed. Macrolide antibiotics chemistry, biology, and practice. 2nd ed. London: Academic Press; 2002.
(check this in PDF content)
19
Bryskier A., Bergogne-Berezin E. Macrolides. In: Bryskier A., ed. Antibacterial and antifungal agents. Washington DC: ASMPress; 2005.
(check this in PDF content)
20
Веселов А.В., Козлов Р.С. Азитромицин: современные аспекты клинического применения. Клин. микробиол. антимикроб. и химиотер. 2006; 8: 71–85.
(check this in PDF content)
21
Козлов Р.С., Сивая О.В., Кречикова О.И. и др.Динамика резистентности Streptococcus pneumoniae к антибиотикам в России за период 1999–2009 гг. Клин. микробиол. антимикроб. химиотер. 2010; 12 (4): 329–341.
(check this in PDF content)
22
Reinert R.R., Filimonova O.Y., Al-Lahham A. et al. Mechanisms of macrolide resistance among Streptococcus pneumoniae isolates from Russia. Antimicrob. Agents Chemother. 2008; 52 (6): 2260–2262.
(check this in PDF content)
23
Козлов Р.С.Пневмококки: уроки прошлого – взгляд в будущее. Смоленск: МАКМАХ; 2010.
(check this in PDF content)
24
EARSS Annual Report 2008. On-going surveillance of S. pneumoniae, S. aureus, E. coli, E. faecium, E. faecalis, K. pneumoniae, P. aeruginosa. http://www.ecdc.europa.eu/en/activities/ surveillance/EARS-Net/Documents/2008_EARSS_Annual_ Report. pdf
(check this in PDF content)
25
Zithromax®(azithromycin tablets). Physician Prescribing Information. Available from: http://labeling.pfizer.com/Show Labeling.aspx?id=511
(check this in PDF content)
26
Zithromax®(azithromycin for injection). Physician Prescribing Information. Available from: http://labeling.pfizer. com/Show Labeling.aspx?id=513
(check this in PDF content)
27
Luke D.R., Foulds G., Cohen S.F., Levy B.Safety, toleration, and pharmacokinetics of intravenous azithromycin. Antimicrob. Agents Chemother. 1996; 40 (11): 2577–2581.
(check this in PDF content)
28
Rodvold K.A., Danziger L.H., Gotfried M.H.Steady-state plasma and bronchopulmonary concentrations of intravenous levofloxacin and azithromycin in healthy adults. Antimicrob. Agents Chemother. 2003; 47 (8): 2450–2457.
(check this in PDF content)
29
Chiu L.M., Menhinick A.M., Johnson P.W., Amsden G.W. Pharmacokinetics of intravenous azithromycin and ceftriaxone when administered alone and concurrently to healthy volunteers. J. Antimicrob. Chemother. 2002; 50 (6): 1075–1079.
(check this in PDF content)
30
Carlier M.B., Scorneaux B., Tulkens P.M.Accumulation, subcellular distribution and activity of azithromycin (Az) compared to roxithromycin (Rx) and ciprofloxacin (Cp) in J774 macrophages (Mo) (abstract). In: 31stinterscience conference on antimicrobial agents and chemotherapy, 1991.
(check this in PDF content)
31
Girard A.E., Cimochowski C.R., Faiella J.A.Correlation of increased azithromycin concentrations with phagocyte infiltration into sites of localized infection. J. Antimicrob. Chemother. 1996; 37 (Suppl. С): 9–19.
(check this in PDF content)
32
Rapp R.P. Pharmacokinetics and pharmacodynamics of intravenous and oral azithromycin: enhanced tissue activity and minimal drug interactions. Ann. Pharmacother. 1998; 32 (7–8): 785–793.
(check this in PDF content)
33
Rodvold K.A.Pharmacodynamics of antiinfective therapy: taking what we know to the patient's bedside. Pharmacotherapy 2001; 21 (Suppl. 2): 319S–330S.
(check this in PDF content)
34
Sevillano D., Alou L., Aguilar L. et al. Azithromycin iv pharmacodynamic parameters predicting Streptococcus pneumoniae killing in epithelial lining fluid versus serum: an in vitro pharmacodynamic simulation. J. Antimicrob. Chemother. 2006; 57 (6): 1128–1133.
(check this in PDF content)
35
Fogarty C., Goldschmidt R., Bush K.Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin. Clin. Infect. Dis. 2000; 31: 613–615.
(check this in PDF content)
36
Foulds G., Shepard R.M., Johnson R.B. The pharmacokinetics of azithromycin in human serum and tissues. J. Antimicrob. Chemother. 1990; 25 (Suppl. A): 73–82.
(check this in PDF content)
37
Periti P., Mazzei T., Mini E., Novelli A. Pharmacokinetic drug interactions of macrolides. Clin. Pharmacokinet. 1992; 23: 106–131.
(check this in PDF content)
38
Стецюк О.У., Андреева И.В., Колосов А.В., Козлов Р.С. Безопасность и переносимость антибиотиков в амбулаторной практике. Клин. микробиол. и антимикроб. химиотер. 2011; 13 (1): 67–84.
(check this in PDF content)
39
Garey K.W., Amsden G.W. Intravenous azithromycin. Ann. Pharmacother. 1999; 33 (2): 218–228.
(check this in PDF content)
40
Zimmerman T., Laufen H., Riedel K.D. et al.Comparative tolerability of intravenous azithromycin, clarithromycin and erythromycin in healthy volunteers: results of a double-blind, doubledummy, four-way crossover study. Clin. Drug Invest. 2001; 21 (8).
(check this in PDF content)
41
Luke D.R., Foulds G.Toleration of intravenous azithromycin. Ann. Pharmacother. 1997; 31: 965–969.
(check this in PDF content)
42
Vergis E.N., Indorf A., File T.M. Jr. et al.Azithromycin vs cefuroxime plus erythromycin for empirical treatment of community-acquired pneumonia in hospitalized patients: a prospective, randomized, multicenter trial. Arch. Intern. Med. 2000; 160 (9): 1294–1300.
(check this in PDF content)
43
Plouffe J., Schwartz D.B., Kolokathis A. et al. Clinical efficacy of intravenous followed by oral azithromycin monotherapy in hospitalized patients with community-acquired pneumonia. Antimicrob. Agents Chemother. 2000; 44 (7): 1796–1802.
(check this in PDF content)
44
Kuzman I., Dakovic-Rode O., Oremus M., Banaszak A.M. Clinical efficacy and safety of a short regimen of azithromycin sequential therapy vs standard cefuroxime sequential therapy in the treatment of community-acquired pneumonia: an international, randomized, open-label study. J. Chemother. 2005; 17 (6): 636–642.
(check this in PDF content)
45
Paladino J.A., Gudgel L.D., Forrest A., Niederman M.S.Costeffectiveness of IV-to-oral switch therapy: azithromycin vs cefuroxime with or without erythromycin for the treatment of community-acquired pneumonia. Chest 2002; 122 (4): 1271–1279.
(check this in PDF content)
46
Синопальников А.И., Зайцев А.А.Клиническая эффективность и безопасность ступенчатой монотерапии азитромицином у пациентов с внебольничной пневмонией в условиях стационара. Фарматека 2006; 16 (131): 66–72.
(check this in PDF content)
47
Plouffe J.F., Breiman R.F., Fields B.S. et al.Azithromycin in the treatment of Legionella pneumonia requiring hospitalization. Clin. Infect. Dis. 2003; 37 (11): 1475–1480.
(check this in PDF content)
48
Rubio F.G., Cunha C.A., Lundgren F.L. et al.Intravenous azithromycin plus ceftriaxone followed by oral azithromycin for the treatment of inpatients with community-acquired pneumonia: an open-label, non-comparativemulticenter trial. Braz. J. Infect. Dis. 2008; 12 (3): 202–209.
(check this in PDF content)
49
Todisco T., Dal Farra F., Ciliberti G. et al. An Italian experience of sequential intravenous and oral azithromycin plus intravenous ampicillin / sulbactam in hospitalized patients with community-acquired pneumonia. J. Chemother. 2008; 20 (2): 225–232.
(check this in PDF content)
50
Frank E., Liu J., Kinasewitz G. et al.A multicenter, open-label, randomized comparison of levofloxacin and azithromycin plus ceftriaxone in hospitalized adults with moderate to severe community-acquired pneumonia. Clin. Ther. 2002; 24 (8): 1292–1308.
(check this in PDF content)
51
Zervos M., Mandell L.A., Vrooman P.S. et al.Comparative efficacies and tolerabilities of intravenous azithromycin plus ceftriaxone and intravenous levofloxacin with step-down oral therapy for hospitalized patients with moderate to severe community-acquired pneumonia. Treat. Respir. Med. 2004; 3 (5): 329–336.
(check this in PDF content)
52
Tamm M., Todisco T., Feldman C. et al. Clinical and bacteriological outcomes in hospitalised patients with communityacquired pneumonia treated with azithromycin plus ceftriaxone, or ceftriaxone plus clarithromycin or erythromycin: a prospective, randomised, multicentre study. Clin. Microbiol. Infect. 2007; 13 (2): 162–171.
(check this in PDF content)
53
Молчанова О.В., Сулейманов С.Ш., Островский А.Б. Антибиотикотерапия тяжелой внебольничной пневмонии. Антибиотики и химиотер. 2009; 54 (3–4): 29–31.
(check this in PDF content)
54
Brito V., Niederman M.S. Pneumonia complicating pregnancy. Clin. Chest Med. 2011; 32 (1): 121–132.
(check this in PDF content)
55
Bosker G., Amin A., Emerman C.L. et al.Optimizing antibiotic selection for CAP and CUTI in the emergency department and hospital setting: a systematic review and evidence-based treatment recommendations – year 2005 update. In: Hospital medicine consensus reports. January 1, 2005.
(check this in PDF content)
56
Niederman M., Mandell L., Anzueto A. et al.Guidelines for the management of adults with community-acquired pneumonia. Diagnosis, assessment of severity, antimicrobial therapy, and prevention. Am. J. Respir. Crit. Care Med. 2001; 163: 1730–1754. Информация об авторах
(check this in PDF content)